Mirogabalin is approved in Japan and several Asian countries for diabetic peripheral neuropathic pain and postherpetic neuralgia. It has higher binding affinity and slower dissociation from α2δ-1 subunits compared to pregabalin, potentially offering improved analgesic effects with fewer CNS side effects. Dose adjustments are necessary for renal impairment: 50% reduction for moderate impairment (CrCl 30-60 mL/min) and 75% reduction for severe impairment. Most common side effects include dizziness (8-16%), somnolence (6-29%), peripheral edema, headache, and weight gain. Not effective for fibromyalgia in clinical trials.
Мирогабалин molecular structure diagram from the DrugsPRO substance library.
Also known as: Tarlige, Ds-5565, Mirogabalin besylate, Mirogabalin monobenzenesulfonate
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Mirogabalin - гид по веществам DrugsPRO
Mirogabalin: Mirogabalin is approved in Japan and several Asian countries for diabetic peripheral neuropathic pain and postherpetic neuralgia. It has higher binding affinity and slower dissociation from α2δ-1 subunits compared to pregabalin, potentially offering improved analgesic effects with fewer
